NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading TMCI? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
TMCI represents a speculative growth investment with a medium confidence level. The current thesis is cautious, as the company is loss-making and its management is neutral on performance.
The market currently prices TMCI as cheap compared to its peers, with a notable expectations gap. This suggests that investors are not overly optimistic about future performance, reflecting the company's recent struggles.
Management is on track to reduce cash usage significantly and is maintaining revenue guidance for 2026. However, the company is still loss-making, and its recent financial performance has not matched that of its industry peers.
The long-term thesis hinges on the company's ability to meet its revenue guidance and the performance of sector bellwethers like ABT, SYK, and MDT. Any cuts to guidance or negative trends in these peers could lead to unfavorable outcomes.
Over the next 1 to 3 years, TMCI's performance will depend on both its execution and broader sector trends. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will show how the company is doing. It will also hint at future plans.
Confirms one read:The earnings report shows a profit. It also beats what analysts expected.
Confirms the other:The earnings report shows a loss. It also misses what analysts expected.
Why it matters: Earnings results will show how much money the company makes. They will also show how well the company runs its operations.
Confirms one read:Q2 earnings show revenue growth or stabilization compared to Q1.
Confirms the other:Q2 earnings reveal further revenue decline compared to Q1.
Why it matters: If the healthcare sector's revenue growth picks up, it may help Treace Medical's performance. This could indicate a better market environment.
Confirms:Healthcare sector revenue growth returns to above 10% year over year.
Disproves:Healthcare sector revenue growth is slowing down. It is now below 10% year over year.
Why it matters: The company aims to maintain its revenue guidance of $202M to $212M for 2026. Confirmation would show stability.
Confirms:Q2 revenue guidance remains within the range of $202M to $212M.
Disproves:Q2 revenue guidance is revised down below $202M.
Why it matters: The company aims to cut cash usage by 50% in 2026. Progress signals better financial health.
Confirms:Cash usage decreases by at least 25% in Q2 compared to Q1.
Disproves:Cash usage does not decrease or increases in Q2.
